Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New gout pill shows promise in large trial

NCT ID NCT06439602

Disease control Sponsor: Arthrosi Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 01, 2026 · Updated 2 times

Summary

This Phase 3 study tested AR882, a drug designed to lower uric acid levels in people with gout. Over 800 participants took either a 50 mg or 75 mg dose of AR882 or a placebo daily for 12 months. The main goal was to see if AR882 could bring uric acid below 6 mg/dL at 6 months, which is key to preventing gout flares. The trial is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AR882 (a drug to lower uric acid)
What this could lead to
If it works, this could offer a new daily pill to control gout by keeping uric acid levels low and reducing painful flares.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The drug may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

818 people

The number who actually took part.

Started

Jun 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * History of gout * Occurrence of ≥ 2 self-reported gout flares in the last 12 months * Body weight no less than 50 kg * Patients who are NOT on approved urate-lowering therapy (ULT) must have sUA ≥ 7 mg/dL * Patients who are on medically appropriate ULT must have sUA \> 6 mg/dL * Serum creatinine must be \< 3.0 mg/dL and estimated CLcr ≥ 30 mL/min Exclusion Criteria: * Malignancy within 5 years, except for successfully treated basal or squamous cell carcinoma of the skin * Pregnant or breastfeeding * History of symptomatic kidney stones within the past 6 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Arthritis, gouty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Arthritis, Gouty gout Hyperuricemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Arthritis, gouty Gout Gout chronic Hyperuricemia

Contacts and locations

Locations

  • Arthrosi Investigative Site (101)

    Aurora, Colorado, 80014, United States

  • Arthrosi Investigative Site (102)

    Hollywood, Florida, 33024, United States

  • Arthrosi Investigative Site (103)

    Miami, Florida, 33176, United States

  • Arthrosi Investigative Site (104)

    Dallas, Texas, 75251, United States

  • Arthrosi Investigative Site (105)

    Detroit, Michigan, 48076, United States

  • Arthrosi Investigative Site (106)

    Foley, Alabama, 36535, United States

  • Arthrosi Investigative Site (107)

    Tomball, Texas, 77375, United States

  • Arthrosi Investigative Site (110)

    Amarillo, Texas, 79106, United States

  • Arthrosi Investigative Site (111)

    Hampton, Virginia, 23666, United States

  • Arthrosi Investigative Site (112)

    Phoenix, Arizona, 85037, United States

  • Arthrosi Investigative Site (114)

    Tempe, Arizona, 85281, United States

  • Arthrosi Investigative Site (115)

    Coral Gables, Florida, 33134, United States

  • Arthrosi Investigative Site (116)

    Graham, Texas, 76450, United States

  • Arthrosi Investigative Site (117)

    Encinitas, California, 92024, United States

  • Arthrosi Investigative Site (118)

    Hampton, Virginia, 23666, United States

  • Arthrosi Investigative Site (119)

    Kansas City, Missouri, 64151, United States

  • Arthrosi Investigative Site (120)

    Hatboro, Pennsylvania, 19040, United States

  • Arthrosi Investigative Site (121)

    Ann Arbor, Michigan, 48109, United States

  • Arthrosi Investigative Site (122)

    River Forest, Illinois, 48109, United States

  • Arthrosi Investigative Site (124)

    Tomball, Texas, 77377, United States

  • Arthrosi Investigative Site (126)

    Lake Jackson, Texas, 77566, United States

  • Arthrosi Investigative Site (127)

    Round Rock, Texas, 78681, United States

  • Arthrosi Investigative Site (128)

    DeLand, Florida, 32720, United States

  • Arthrosi Investigative Site (129)

    Plano, Texas, 75024, United States

  • Arthrosi Investigative Site (130)

    Wilmington, North Carolina, 28403, United States

  • Arthrosi Investigative Site (131)

    El Cajon, California, 92108, United States

  • Arthrosi Investigative Site (132)

    Rapid City, South Dakota, 57702, United States

  • Arthrosi Investigative Site (133)

    Boise, Idaho, 83713, United States

  • Arthrosi Investigative Site (134)

    Winchester, Virginia, 22601, United States

  • Arthrosi Investigative Site (136)

    Missouri City, Texas, 77459, United States

  • Arthrosi Investigative Site (137)

    Greensboro, North Carolina, 27410, United States

  • Arthrosi Investigative Site (138)

    Rancho Cucamonga, California, 91730, United States

  • Arthrosi Investigative Site (139)

    Anchorage, Alaska, 99508, United States

  • Arthrosi Investigative Site (140)

    Shelby, North Carolina, 28150, United States

  • Arthrosi Investigative Site (142)

    Bountiful, Utah, 98021, United States

  • Arthrosi Investigative Site (144)

    New Orleans, Louisiana, 70115, United States

  • Arthrosi Investigative Site (145)

    Ogden, Utah, 84405, United States

  • Arthrosi Investigative Site (146)

    Dayton, Ohio, 45429, United States

  • Arthrosi Investigative Site (147)

    Myrtle Beach, South Carolina, 29572, United States

  • Arthrosi Investigative Site (148)

    Cleveland, Ohio, 44195, United States

  • Arthrosi Investigative Site (149)

    Clearwater, Florida, 33756, United States

  • Arthrosi Investigative Site (150)

    Hagerstown, Maryland, 21740, United States

  • Arthrosi Investigative Site (151)

    Winter Haven, Florida, 33880, United States

  • Arthrosi Investigative Site (153)

    Olive Branch, Mississippi, 38654-3514, United States

  • Arthrosi Investigative Site (154)

    Wichita, Kansas, 67207, United States

  • Arthrosi Investigative Site (156)

    Maitland, Florida, 32751, United States

  • Arthrosi Investigative Site (157)

    Palmetto Bay, Florida, 91355, United States

  • Arthrosi Investigative Site (158)

    Brooklyn, New York, 11215, United States

  • Arthrosi Investigative Site (160)

    Peoria, Arizona, 85381, United States

  • Arthrosi Investigative Site (161)

    Valencia, California, 28277, United States

  • Arthrosi Investigative Site (162)

    Lilburn, Georgia, 30047, United States

  • Arthrosi Investigative Site (164)

    Atlanta, Georgia, 30329, United States

  • Arthrosi Investigative Site (200)

    Camberwell, Victoria, 3124, Australia

  • Arthrosi Investigative Site (202)

    Botany, New South Wales, 2019, Australia

  • Arthrosi Investigative Site (300)

    Auckland, 1010, New Zealand

  • Arthrosi Investigative Site (301)

    Rotorua, 3010, New Zealand

  • Arthrosi Investigative Site (302)

    Auckland, 0632, New Zealand

  • Arthrosi Investigative Site (303)

    Nelson, 7011, New Zealand

  • Arthrosi Investigative Site (304)

    Hamilton, 3200, New Zealand

  • Arthrosi Investigative Site (400)

    Taipei, 11217, Taiwan

  • Arthrosi Investigative Site (401)

    Taoyuan City, 333, Taiwan

  • Arthrosi Investigative Site (402)

    Taichung, 402, Taiwan

  • Arthrosi Investigative Site (403)

    Taipei, 112, Taiwan

  • Arthrosi Investigative Site (404)

    Kaohsiung City, 833, Taiwan

  • Arthrosi Investigative Site (405)

    Hualien City, Taiwan, 97002, Taiwan

  • Arthrosi Investigative Site (406)

    Kaohsiung City, 813, Taiwan

  • Arthrosi Investigative Site (500)

    Hong Kong, Central, Hong Kong

  • Arthrosi Investigative Site (501)

    Hong Kong, Hong Kong Island, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.